Platinum-based chemotherapy is the first-line therapy for advanced NSCLC patients who lack targetable mutations, but among those with PD-L1 expression ≥ 50%, immune checkpoint inhibitor (ICI) is a preferential option. This evidence concerns the gene CD274 and non-small cell lung carcinoma.